The shares of ImmunoGen, Inc. (NASDAQ:IMGN) has been pegged with a rating of Buy by H.C. Wainwright in its latest research note that was published on August 13th, 2019. The research company has also assigned a $5 price target. H.C. Wainwright wasn’t the only research firm that published a report of ImmunoGen, Inc., with other equities research analysts also giving their opinion on the stock. Guggenheim advised investors in its research note published on May 15th, 2019, to Neutral the IMGN stock. The stock had earned Buy rating from H.C. Wainwright when it published its report on May 6th, 2019. That day the H.C. Wainwright set price target on the stock to $7. The stock was given Outperform rating by Cowen in its report released on May 6th, 2019. JP Morgan was of a view that IMGN is Underweight in its latest report on March 19th, 2019. Morgan Stanley thinks that IMGN is worth Equal-Weight rating. This was contained in the firm’s report on March 5th, 2019.
Amongst the analysts that rated the stock, 0 have recommended investors to sell it, 4 believe it has the potential for further growth, thus rating it as Hold while 2 advised investors to purchase the stock. The consensus currently stands at a Hold while its average price target is $4.67. The price of the stock the last time has raised by 47.16% from its Week high price while it is raised higher than its 52-Week low price. A look at the stock’s other technical shows that its 14-day RSI now stands at 52.67.
The shares of the company dipped by -4.78% during the trading session on Thursday, reaching a low of $2.54 while ending the day at $2.59. During the trading session, a total of 1.38 million shares were traded which represents a 51.79% incline from the average session volume which is 2.87M shares. IMGN had ended its last session trading at 2.72. ImmunoGen, Inc. currently has a market cap of $383.65M while its P/E earnings growth sits at 7.91, with a beta of 2.04. IMGN 52-week low price stands at $1.76 while its 52-week high price is $10.37.
The ImmunoGen, Inc. generated $15.54 million in revenue during the last quarter, which is slightly higher than the $9.48 million predicted by analysts. ImmunoGen, Inc. has the potential to record -1.19 EPS for the current fiscal year, according to equities analysts.
Investment analysts at TD Securities published a research note on May 3rd, 2019 where it informed investors and clients that Osisko Gold Royalties Ltd (NYSE:OR) is now rated as Hold. Guggenheim also rated OR as Downgrade on May 15th, 2019, with its price target of $19 suggesting that OR could down by 0% from its current share price. It started the day trading at $12.39 and traded between $12.17 and $12.26 throughout the trading session.
A look at its technical shows that OR’s 50-day SMA is 11.44 while its 200-day SMA stands at 10.18. At the moment, only of Osisko Gold Royalties Ltd shares were sold short. The company’s average trading volume currently stands at 739.86K shares, which means that the short-interest ratio is just 1.73 days. Over the past seven days, the company moved, with its shift of 0.08%. Looking further, the stock has raised 24.34% over the past 90 days while it gained 7.17% over the last six months.